|
Comprehensive molecular profiling of patients with pancreatic adenocarcinoma: A single institution’s experience. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Benchling (I) |
Stock and Other Ownership Interests - Benchling (I) |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Endocyte; GE Healthcare; Merck; Merrimack; Personal Genome Diagnostics; Siemens Healthcare Diagnostics; Taiho Pharmaceutical |
Speakers' Bureau - GE Healthcare |
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eisai; H3 Biomedicine; Inovio Pharmaceuticals; Karyopharm Therapeutics; Merrimack; Novartis; OncoMed; Plexxikon; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Caris Life Sciences; Endocyte; GE Healthcare; Merrimack |
|
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Merck; Novartis; Rafael Pharmaceuticals; Sanofi |
Consulting or Advisory Role - Celgene; Gilead Sciences; Halozyme; Ipsen; Merck; Merrimack; novartis |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Celgene; Ipsen; Merck |
Research Funding - Bayer (Inst); Genentech (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst) |
Other Relationship - Halozyme |